PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
PERRIGO Co plc
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$16.09−0.54 (-3.25%)
Close on Oct 19, 2026
- Market cap
- $2.25B
- P/E (TTM)
- –
- Dividend yield
- 7.21%
PERRIGO Co plc revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CSCA | – | – | $2.59B | $2.63B | $2.66B | $2.67B | $2.69B | $2.69B | $2.73B | $2.84B | $2.96B | $2.98B | – | – |
| CSCI | – | – | $1.67B | $1.65B | $1.67B | $1.66B | $1.68B | $1.70B | $1.70B | $1.71B | $1.69B | $1.67B | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CSCA | – | – | -$669.00M | $286.60M | $294.10M | $318.30M | $269.90M | $304.80M | $293.70M | $322.10M | $389.60M | $398.10M | – |
| CSCI | – | – | -$228.80M | $176.10M | $187.60M | $118.10M | $105.00M | -$13.70M | -$49.00M | -$29.90M | -$35.20M | -$5.30M | – |
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.50B | $2.49B | $2.54B | $2.59B | $2.61B | $2.63B | $2.65B | $2.66B | $2.69B | $2.80B | $2.92B | $2.93B | 60.3% | -4.2% |
| Europe | $1.55B | $1.60B | $1.62B | $1.60B | $1.61B | $1.60B | $1.60B | $1.62B | $1.62B | $1.64B | $1.62B | $1.61B | 37.3% | -4.0% |
| All other countries | $98.70M | $97.70M | $96.70M | $97.00M | $106.30M | $111.90M | $119.50M | $119.20M | $119.60M | $121.90M | $116.30M | $116.20M | 2.4% | -7.1% |
| Ireland | $33.10M | $35.20M | $42.10M | $42.20M | $44.70M | $46.30M | $39.60M | $36.60M | $37.40M | $37.90M | $40.80M | $40.30M | 0.8% | -26.0% |
From the segment and revenue-disaggregation notes of Perrigo's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.